← All trials
NCT01488526
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- Apr 28, 2014
- Completion date
- Oct 28, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- New Discovery LLCLead sponsor
- Hepatobiliary Disease Hospital of Jilin Province, Jilin, ChinaOverall official - principal investigator
- The Fifth Hospital of ShijiazhuangOverall official - principal investigator
- Southeast UniversityOverall official - principal investigator
- Nanyang Central HospitalOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- Capital Medical UniversityStudy director
- New York UniversityStudy chair
- Gilead SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.